title: [Peculiarities of immunomodulating therapy in an immunocompromised patient with allergies].
abstract: The authors summarize recent data on the predisposition to, indications for, and efficacy of immunomodulating therapy of immunocompromised patients presenting with allergia. Clinical and immunological characteristic of pathology is presented including cytokine status before and after therapy. High efficacy of immunomodulators like interferons is exemplified by the most efficacious of them, cycloferon (meglumin acridonacetate). Disturbed immune reactivity promotes the development of pathological process. Results of the studies of various aspects of immunogenesis suggest desirability of inclusion of cycloferon therapy in the combined treatment of the disease under consideration. New aspects of clinical use of the immunomodulator cycloferon in combination with allergen-specific immunotherapy are discussed.
mesh_terms: D000166:Acridines / Q000009:adverse effects / Q000627:therapeutic use*; D003888:Desensitization, Immunologic / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006801:Humans; D016867:Immunocompromised Host; D056747:Immunomodulation; D007369:Interferon Inducers / Q000009:adverse effects / Q000627:therapeutic use*; D009894:Opportunistic Infections / Q000188:drug therapy*
chemical_list: D000166:Acridines; D007369:Interferon Inducers; C026430:10-carboxymethyl-9-acridanone